1332529-63-1

Basic information

• Product Name: 3-{[(3-Fluorobenzyl)oxy]methyl}-1-methyl-4,5,6,7-t etrahydro-1H-pyrazolo[4,3-c]pyridine hydrochlorid
• Synonyms: 3-{[(3-Fluorobenzyl)oxy]methyl}-1-methyl-4,5,6,7-t etrahydro-1H-pyrazolo[4,3-c]pyridine hydrochlorid;3-{[(3-Fluorobenzyl)oxy]methyl}-1-methyl-4,5,6,7-t etrahydro-1H-pyrazolo[4,3-c]pyridine hydrochlo;3-{[(3-fluorobenzyl)oxy]methyl}-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine hydrochloride;3-{[(3-Fluorobenzyl)oxy]methyl}-1-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine hydroch;3-[(3-fluorophenyl)methoxymethyl]-1-methyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine:hydrochloride
• CAS NO: 1332529-63-1
• Molecular Formula: C15H19ClFN3O
• Molecular Weight: 311.7822632
• Mol File: 1332529-63-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-{[(3-Fluorobenzyl)oxy]methyl}-1-methyl-4,5,6,7-t etrahydro-1H-pyrazolo[4,3-c]pyridine hydrochlorid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{[(3-Fluorobenzyl)oxy]methyl}-1-methyl-4,5,6,7-t etrahydro-1H-pyrazolo[4,3-c]pyridine hydrochlorid(1332529-63-1)
• EPA Substance Registry System: 3-{[(3-Fluorobenzyl)oxy]methyl}-1-methyl-4,5,6,7-t etrahydro-1H-pyrazolo[4,3-c]pyridine hydrochlorid(1332529-63-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1332529-63-1(Hazardous Substances Data)

Upstream product

• 518990-23-3 5‐tert‐butyl 3‐ethyl 1,4,6,7‐tetrahydro‐5H‐pyrazolo[4,3‐c]pyridine‐3,5‐dicarboxylate 
• 1142210-81-8 5-(tert-butyl) 3-ethyl 1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate 

Relevant articles and documents

Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875)

Three types of heterocyclic moieties—piperidines fused to a heteroaromatic moiety—were explored as potential periphery motifs for the pharmacophoric core of fasiglifam (TAK-875), with fasiglifam being the most advanced agonist of free fatty acid receptor 1, a promising target for therapeutic intervention in type 2 diabetes. Several observed structure–activity relationship trends were corroborated by in silico docking results. Balanced selection based on potency and Caco-2 permeability advanced six compounds to cellular efficacy tests (glucose-stimulated insulin secretion in rat insulinoma INS1E cells). This led to the nomination of compound 16a (LK1408, 3-[4-({4-[(3-{[(2-fluorobenzyl)oxy]methyl}-1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)methyl]benzyl}oxy)phenyl]propanoic acid hydrochloride) as the lead for further development.